SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 18, 2004
GUILFORD PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 0-23736 | | 52-1841960 |
|
| (State or other jurisdiction of | | (Commission File | | (I.R.S. Employer |
| incorporation or organization) | | Number) | | Identification No.) |
| | | |
| 6611 Tributary Street | | |
| Baltimore, Maryland | | 21224 |
|
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (410) 631-6300
|
| (Former name or former address, if changed since last report) |
INFORMATION TO BE INCLUDED IN THE REPORT
Item 5. Other Events
On June 18, 2004, Guilford Pharmaceuticals Inc. issued a press release announcing that it has licensed to Symphony Neuro Development Company its U.S. rights to GPI 1485, a novel compound based on Guilford’s neuroimmunophilin ligand technology, in four indications: Parkinson’s disease, post-prostatectomy erectile dysfunction, HIV-neuropathy and HIV-dementia. A copy of Guilford’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements,Pro FormaFinancial Information and Exhibits
(c) Exhibits
99.1 Press Release of Guilford Pharmaceuticals Inc. issued June 18, 2004.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | Guilford Pharmaceuticals Inc. |
| | | | | |
| | | | | |
| Date: June 18, 2004 | | By: | | /s/ Asher M. Rubin
Asher M. Rubin
Vice President, General Counsel
and Secretary |
2
INDEX TO EXHIBITS
| | | |
| Exhibit | | |
| Number | | Exhibit Description |
| | | |
| 99.1 | | Press Release of Guilford Pharmaceuticals Inc. issued June 18, 2004. |
3
